Motivation:

For turning academic cross-functional research into a marketed solution that addresses the rising need for biomarker identification and early diagnosis of lung disease through non-invasive measurement of the small airways.

Diseases of the lung represents an area of significant unmet medical need and increasing global prevalence, where the emergence of personalised medicine can make a huge difference with the support of effective biomarker analysis.

Anna-Carin Olin and her team show true entrepreneurship in offering both a product for immediate use in today’s research, as well as pioneering the implementation of new diagnostic standards enabling future use of novel treatment options.